Agenus Inc. Announces New Clinical Study Highlighting Promising Survival Plateaus with Botensilimab/Balstilimab in Refractory Cancer Patients at ESMO 2025

Reuters

2025/07/26

Agenus Inc. Announces New Clinical Study Highlighting Promising Survival Plateaus with Botensilimab/Balstilimab in Refractory Cancer Patients at ESMO 2025

Agenus Inc., a leader in immuno-oncology, has announced that four abstracts related to their botensilimab and balstilimab immunotherapy programs have been accepted for presentation at the upcoming European Society for Medical Oncology (ESMO) Congress 2025, to be held in Berlin, Germany, from October 17-21, 2025. The presentations will highlight the clinical progress of these therapies in treating refractory metastatic solid tumors across five tumor types. The key event is an oral presentation focusing on emerging survival plateaus from a study involving 343 evaluable patients, to be presented by Dr. Michael Gordon from HonorHealth Research Institute, USA, on October 17. Additional poster presentations will cover data from studies on cervical cancer, MSS metastatic colorectal cancer, and non-melanoma skin cancers, showcasing the potential of these immunotherapy combinations in treating difficult-to-treat cancers. These results will be presented in the future at the specified dates and times during the congress.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agenus Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250725773112) on July 25, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2554960767"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2554960767\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2554960767?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-26 00:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2554960767","market":"nz","top_or_hot":-1,"title":"Agenus Inc. Announces New Clinical Study Highlighting Promising Survival Plateaus with Botensilimab/Balstilimab in Refractory Cancer Patients at ESMO 2025","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Agenus Inc. Announces New Clinical Study Highlighting Promising Survival Plateaus with Botensilimab/Balstilimab in Refractory Cancer Patients at ESMO 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Agenus Inc., a leader in immuno-oncology, has announced that four abstracts related to their botensilimab and balstilimab immunotherapy programs have been accepted for presentation at the upcoming European Society for Medical Oncology (ESMO) Congress 2025, to be held in Berlin, Germany, from October 17-21, 2025. The presentations will highlight the clinical progress of these therapies in treating refractory metastatic solid tumors across five tumor types. The key event is an oral presentation focusing on emerging survival plateaus from a study involving 343 evaluable patients, to be presented by Dr. Michael Gordon from HonorHealth Research Institute, USA, on October 17. Additional poster presentations will cover data from studies on cervical cancer, MSS metastatic colorectal cancer, and non-melanoma skin cancers, showcasing the potential of these immunotherapy combinations in treating difficult-to-treat cancers. These results will be presented in the future at the specified dates and times during the congress.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agenus Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250725773112) on July 25, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Agenus Inc. Announces New Clinical Study Highlighting Promising Survival Plateaus with Botensilimab/Balstilimab in Refractory Cancer Patients at ESMO 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAgenus Inc. Announces New Clinical Study Highlighting Promising Survival Plateaus with Botensilimab/Balstilimab in Refractory Cancer Patients at ESMO 2025\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-07-26 00:46</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Agenus Inc. Announces New Clinical Study Highlighting Promising Survival Plateaus with Botensilimab/Balstilimab in Refractory Cancer Patients at ESMO 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Agenus Inc., a leader in immuno-oncology, has announced that four abstracts related to their botensilimab and balstilimab immunotherapy programs have been accepted for presentation at the upcoming European Society for Medical Oncology (ESMO) Congress 2025, to be held in Berlin, Germany, from October 17-21, 2025. The presentations will highlight the clinical progress of these therapies in treating refractory metastatic solid tumors across five tumor types. The key event is an oral presentation focusing on emerging survival plateaus from a study involving 343 evaluable patients, to be presented by Dr. Michael Gordon from HonorHealth Research Institute, USA, on October 17. Additional poster presentations will cover data from studies on cervical cancer, MSS metastatic colorectal cancer, and non-melanoma skin cancers, showcasing the potential of these immunotherapy combinations in treating difficult-to-treat cancers. These results will be presented in the future at the specified dates and times during the congress.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agenus Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250725773112) on July 25, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AGEN","symbol_name":"艾吉納斯公司","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250725:nNDL9K5gWt:1","article_id":"2554960767","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2554960767","pubTimestamp":1753461980,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Agenus Inc., a leader in immuno-oncology, has announced that four abstracts related to their botensilimab and balstilimab immunotherapy programs have been accepted for presentation at the upcoming European Society for Medical Oncology  Congress 2025, to be held in Berlin, Germany, from October 17-21, 2025. The presentations will highlight the clinical progress of these therapies in treating refractory metastatic solid tumors across five tumor types. The key event is an oral presentation focusing on emerging survival plateaus from a study involving 343 evaluable patients, to be presented by Dr. Michael Gordon from HonorHealth Research Institute, USA, on October 17. Additional poster presentations will cover data from studies on cervical cancer, MSS metastatic colorectal cancer, and non-melanoma skin cancers, showcasing the potential of these immunotherapy combinations in treating difficult-to-treat cancers. These results will be presented in the future at the specified dates and times d","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"AGEN":"艾吉纳斯公司","BK4139":"生物科技"},"translate_title":"Agenus Inc.在ESMO 2025上宣布新的临床研究，强调Botensilimab/Balstilimab在难治性癌症患者中的生存平台期","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AGEN":0.9},"content_text":"Agenus Inc. Announces New Clinical Study Highlighting Promising Survival Plateaus with Botensilimab/Balstilimab in Refractory Cancer Patients at ESMO 2025\n    \n\n        Agenus Inc., a leader in immuno-oncology, has announced that four abstracts related to their botensilimab and balstilimab immunotherapy programs have been accepted for presentation at the upcoming European Society for Medical Oncology (ESMO) Congress 2025, to be held in Berlin, Germany, from October 17-21, 2025. The presentations will highlight the clinical progress of these therapies in treating refractory metastatic solid tumors across five tumor types. The key event is an oral presentation focusing on emerging survival plateaus from a study involving 343 evaluable patients, to be presented by Dr. Michael Gordon from HonorHealth Research Institute, USA, on October 17. Additional poster presentations will cover data from studies on cervical cancer, MSS metastatic colorectal cancer, and non-melanoma skin cancers, showcasing the potential of these immunotherapy combinations in treating difficult-to-treat cancers. These results will be presented in the future at the specified dates and times during the congress.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agenus Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250725773112) on July 25, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}